The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prospective assessment of circulating endothelial cells (CECs) as pharmacodynamic marker in first line clear cell renal cell carcinoma (CCRCC): The CIRCLES study (SOGUG 2011-01).
Daniel E. Castellano
Research Funding - Novartis; Pfizer
Expert Testimony - Novartis
Emilio Esteban
No relevant relationships to disclose
Luis Leon Mateos
No relevant relationships to disclose
Aranzazu Gonzalez del Alba
No relevant relationships to disclose
Maria Jose Mendez Vidal
No relevant relationships to disclose
Jose Angel Arranz Arija
No relevant relationships to disclose
Xavier Garcia del Muro
No relevant relationships to disclose
Laura Basterretxea
No relevant relationships to disclose
Miguel Angel Climent Duran
No relevant relationships to disclose
Juan Antonio Virizuela
No relevant relationships to disclose
Francisco Javier Perez
No relevant relationships to disclose
Susana Hernando Polo
No relevant relationships to disclose
Jesús García-Donas
Honoraria - Novartis
Research Funding - Novartis; Pfizer; Takeda